Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma GroupFRA:LUP +2.65%41 EV-to-EBITDA is 4.91 as of Aug. 09, 2026, which is 45% below its 10-year median of 8.89. GuruFocus rates FRA:LUP with a GF Score™ of 41/100 and a GF Value™ of €0.32 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 737 Drug Manufacturers companies, Luye Pharma Group ranks better than 86.7% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Luye Pharma Group's enterprise value is €1,467.8 Mil.
Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €299.0 Mil. Therefore, Luye Pharma Group's EV-to-EBITDA for today is 4.91.
The historical rank and industry rank for Luye Pharma Group's EV-to-EBITDA or its related term are showing as below:
FRA:LUP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.24 Med: 8.89 Max: 18.21
Current: 4.89
During the past 13 years, the highest EV-to-EBITDA of Luye Pharma Group was 18.21. The lowest was 4.24. And the median was 8.89.
FRA:LUP's EV-to-EBITDA is ranked better than 86.7% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.28
vs FRA:LUP: 4.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Luye Pharma Group (FRA:LUP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Luye Pharma Group's PE Ratio (TTM) for today is calculated as:
Luye Pharma Group's share price for today is €0.232.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.019.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Luye Pharma Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's EV-to-EBITDA falls into.
Luye Pharma Group's current Enterprise Value is €1,467.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €299.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a EV-to-EBITDA of 4.91 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Luye Pharma Group. This is 45% below median its historical median of 8.89. Over the past decade, Luye Pharma Group's EV-to-EBITDA has ranged from 4.24 to 18.21. According to the industry distribution chart, Luye Pharma Group ranks #98 out of 737 companies in the Drug Manufacturers industry, placing it in the top 13.3%.
Is Luye Pharma Group's EV-to-EBITDA too high?
Luye Pharma Group's current EV-to-EBITDA of 4.91 is 45% below median its 10-year median of 8.89. Over the past 10 years, this metric has ranged from a low of 4.24 to a high of 18.21. The Drug Manufacturers industry median EV-to-EBITDA is 13.28. Luye Pharma Group's value of 4.91 is 63% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #98 out of 737 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #98 out of 737 companies for EV-to-EBITDA. This places Luye Pharma Group in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.28. Luye Pharma Group's value of 4.91 is 63% below this benchmark. Historically, Luye Pharma Group's own EV-to-EBITDA has ranged from 4.24 to 18.21 over the past decade. While the company's 10-year median is 8.89 vs. the industry median of 13.28, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.28, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current EV-to-EBITDA of 4.91 is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Luye Pharma Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current EV-to-EBITDA is 4.91, which is 45% below median its own 10-year median of 8.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.23 — trading 27.5% below its estimated fair value. The current EV-to-EBITDA is 4.91, which is 45% below median its 10-year median of 8.89 and 63% below the Drug Manufacturers industry median of 13.28. Luye Pharma Group's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current EV-to-EBITDA is 4.91 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.23 is trading 27.5% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Modestly Undervalued.
Key valuation signals for FRA:LUP:
EV-to-EBITDA: 4.91 (45% below median its 10-year median of 8.89)
GF Value™: €0.32 vs. price of €0.23 (27.5% below fair value)
Industry Position: 63% below the Drug Manufacturers median (#98 of 737)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
41GF Score
Get the complete analysis for FRA:LUP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
